Marker Therapeutics (MRKR) FCF Margin (2016 - 2025)
Historic FCF Margin for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 221.9%.
- Marker Therapeutics' FCF Margin fell 2840700.0% to 221.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 873.6%, marking a year-over-year increase of 10113200.0%. This contributed to the annual value of 5455.16% for FY2024, which is 49586600.0% down from last year.
- As of Q3 2025, Marker Therapeutics' FCF Margin stood at 221.9%, which was down 2840700.0% from 218.11% recorded in Q2 2025.
- In the past 5 years, Marker Therapeutics' FCF Margin registered a high of 191.99% during Q2 2022, and its lowest value of 1575.39% during Q1 2025.
- Moreover, its 4-year median value for FCF Margin was 241.21% (2023), whereas its average is 471.39%.
- Per our database at Business Quant, Marker Therapeutics' FCF Margin soared by 12680900bps in 2023 and then tumbled by -12669500bps in 2025.
- Quarter analysis of 4 years shows Marker Therapeutics' FCF Margin stood at 827.34% in 2022, then soared by 73bps to 224.09% in 2023, then skyrocketed by 151bps to 113.62% in 2024, then plummeted by -295bps to 221.9% in 2025.
- Its FCF Margin was 221.9% in Q3 2025, compared to 218.11% in Q2 2025 and 1575.39% in Q1 2025.